Harewood L - Search Results

1

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP. Lawrence MG, et al. Among authors: harewood l. Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23. Eur Urol. 2018. PMID: 30049486 Free PMC article.

2

Transitional cell carcinoma growing along an indwelling nephrostomy tube track.

Sengupta S, Harewood L. Sengupta S, et al. Among authors: harewood l. Br J Urol. 1998 Oct;82(4):591. doi: 10.1046/j.1464-410x.1998.00784.x. Br J Urol. 1998. PMID: 9806197 No abstract available.

3

A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects.

Beilin J, Harewood L, Frydenberg M, Mameghan H, Martyres RF, Farish SJ, Yue C, Deam DR, Byron KA, Zajac JD. Beilin J, et al. Among authors: harewood l. Cancer. 2001 Aug 15;92(4):941-9. doi: 10.1002/1097-0142(20010815)92:4<941::aid-cncr1404>3.0.co;2-p. Cancer. 2001. PMID: 11550169

4

Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup.

Hong MK, Namdarian B, Corcoran NM, Pedersen J, Murphy DG, Peters JS, Harewood L, Sapre N, Rzetelski-West K, Costello AJ, Hovens CM. Hong MK, et al. Among authors: harewood l. Pathology. 2011 Feb;43(2):138-42. doi: 10.1097/PAT.0b013e3283420155. Pathology. 2011. PMID: 21233675

5

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL. Corcoran NM, et al. Among authors: harewood l. BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15. BJU Int. 2012. PMID: 22085203

6

Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease.

Corcoran NM, Hovens CM, Metcalfe C, Hong MK, Pedersen J, Casey RG, Peters J, Harewood L, Goldenberg SL, Costello AJ, Gleave ME. Corcoran NM, et al. Among authors: harewood l. BJU Int. 2012 Sep;110(6):821-7. doi: 10.1111/j.1464-410X.2011.10868.x. Epub 2012 Jan 18. BJU Int. 2012. PMID: 22257140

7

Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status.

Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L; Australian Prostate Cancer Bioresource; Collins AT, Maitland NJ, Risbridger GP. Taylor RA, et al. Among authors: harewood l. Stem Cells. 2012 Jun;30(6):1087-96. doi: 10.1002/stem.1094. Stem Cells. 2012. PMID: 22593016

8

Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.

Mills J, Oliver A, Sherwin JC, Frydenberg M, Peters JS, Costello A, Harewood L, Love C, Redgrave N, van Golen KL, Bailey M, Pedersen J. Mills J, et al. Among authors: harewood l. Pathology. 2012 Oct;44(6):513-8. doi: 10.1097/PAT.0b013e3283581780. Pathology. 2012. PMID: 22935975

9

Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer.

Sapre N, Pedersen J, Hong MK, Harewood L, Peters J, Costello AJ, Hovens CM, Corcoran NM. Sapre N, et al. Among authors: harewood l. BJU Int. 2012 Dec;110 Suppl 4:58-63. doi: 10.1111/j.1464-410X.2012.11477.x. BJU Int. 2012. PMID: 23194127

10

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM. Huang JG, et al. BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23350712

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters